Effects of the PPARγ agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse

Toxicology and Applied Pharmacology

Volumn 237, Issue 1, 2009, Pages 83-90

  Kakiuchi Kiyota, Satoko ^a   Vetro, Joseph A ^b   Suzuki, Shugo ^a   Varney, Michelle L ^a   Han, Huai Yun ^b   Nascimento, Merielen ^a   Pennington, Karen L ^a   Arnold, Lora L ^a   Singh, Rakesh K ^a   Cohen, Samuel M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Endothelial cell; Hemangiosarcoma; PPAR ; Proliferation; Troglitazone

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BROWN ADIPOSE TISSUE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HEART WEIGHT; HEMANGIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LC 50; LIVER CELL; MAMMARY GLAND; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES DIFFERENCE; VASCULAR TUMOR; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; CARCINOGEN TESTING; CELL CULTURE; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG POTENTIATION; GENETICS; LD 50; LONGITUDINAL STUDY; METABOLISM; NONPARAMETRIC TEST; RANDOMIZATION;

MUS; RATTUS; RODENTIA;

ADIPOSE TISSUE; ANIMALS; CARCINOGENICITY TESTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HEMANGIOSARCOMA; HUMANS; LETHAL DOSE 50; LONGITUDINAL STUDIES; MICE; MICROVESSELS; PPAR GAMMA; RANDOM ALLOCATION; RNA, MESSENGER; SPECIES SPECIFICITY; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 66549118830     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.02.028     Document Type: Article

References (40)

1. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., and Lawley T.J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99 (1992) 683-690
2. Aoki T. Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J. Toxicol. Pathol. 20 (2007) 197-202
3. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
4. Biscetti F., Gaetani E., Flex A., Aprahamian T., Hopkins T., Straface G., Pecorini G., Stigliano E., Smith R.C., Angelini F., Castellot Jr. J.J., and Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57 (2008) 1394-1404
5. Bishop-Bailey D., and Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta12, 14-prostaglandin J2. J. Biol. Chem. 274 (1999) 17042-17048
6. Breider M.A., Gough A.W., Haskins J.R., Sobocinski G., and de la Iglesia F.A. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol. Pathol. 27 (1999) 545-552
7. Cannon B., and Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84 (2004) 277-359
8. Cohen S.M., and Ellwein L.B. Cell proliferation in carcinogenesis. Science 249 (1990) 1007-1011
9. Cohen S.M., and Ellwein L.B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51 (1991) 6493-6505
10. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., Duriez P., and Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85 (1999) 394-402
11. Duddy S.K., Gorospe S.M., Bleavins M.R., and de la Iglesia F.A. Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol. Appl. Pharmacol. 160 (1999) 133-140
12. Duddy S.K., Parker R.F., Bleavins M.R., Gough A.W., Rowse P.E., Gorospe S., Dethloff L.A., and de la Iglesia F.A. p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol. Appl. Pharmacol. 156 (1999) 106-112
13. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., and Koeffler H.P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8806-8811
14. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272 (1997) 18779-18789
15. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192 (2007) 67-74
16. Gimble J.M., Pighetti G.M., Lerner M.R., Wu X., Lightfoot S.A., Brackett D.J., Darcy K., and Hollingsworth A.B. Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochem. Biophys. Res. Commun. 253 (1998) 813-817
17. Herman J.R., Dethloff L.A., McGuire E.J., Parker R.F., Walsh K.M., Gough A.W., Masuda H., and de la Iglesia F.A. Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol. Sci. 68 (2002) 226-236
18. Hirano K., Hagiwara T., Umezawa T., Uchida T., Watanabe M., and Matsushima H. Mutagenicity studies of CS-045 in bacteria, in mammalian tissue culture cells and in mice. Rinsho Iyaku 9 (1993) 375-388
19. Jat P.S., Noble M.D., Ataliotis P., Tanaka Y., Yannoutsos N., Larsen L., and Kioussis D. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 5096-5100
20. Jiang Y.J., Hatch G.M., Mymin D., Dembinski T., Kroeger E.A., and Choy P.C. Modulation of cytosolic phospholipase A(2) by PPAR activators in human preadipocytes. J. Lipid. Res. 42 (2001) 716-724
21. Jozkowicz A., Dulak J., Prager M., Nanobashvili J., Nigisch A., Winter B., Weigel G., and Huk I. Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner. Prostaglandins Other Lipid Mediat. 66 (2001) 165-177
22. Jozkowicz A., Huk I., Nigisch A., Cisowski J., Weigel G., and Dulak J. Prostaglandin-J(2) upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor-gamma. Acta Biochim. Pol. 50 (2003) 677-689
23. Langley R.R., Ramirez K.M., Tsan R.Z., Van Arsdall M., Nilsson M.B., and Fidler I.J. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 63 (2003) 2971-2976
24. Lee K.S., Park J.H., Lee S., Lim H.J., Jang Y., and Park H.Y. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem. Biophys. Res. Commun. 346 (2006) 83-88
25. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
26. Loi C.M., Young M., Randinitis E., Vassos A., and Koup J.R. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 37 (1999) 91-104
27. Martin R.A., Daly A., DiFonzo C.J., and de la Iglesia F.A. Randomization of animals by computer program for toxicity studies. J. Environ. Pathol. Toxicol. Oncol. 6 (1986) 143-152
28. Moraes L.A., Piqueras L., and Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 110 (2006) 371-385
29. Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., Zhang M., Fletcher C., Singer S., and Spiegelman B.M. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1 (1998) 465-470
30. National Toxicology Program, (2000). NIEHS Internet Website: http://ntp.niehs.nih.gov/index.cfm?objectid=92E6AAA5-F1F6-975E-71C88528A 3E7B315#5.
31. Ohnishi T., Arnold L.L., Clark N.M., Wisecarver J.L., and Cohen S.M. Comparison of endothelial cell proliferation in normal liver and adipose tissue in B6C3F1 mice, F344 rats, and humans. Toxicol. Pathol. 35 (2007) 904-909
32. Panigrahy D., Shen L.Q., Kieran M.W., and Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Investig. Drugs 12 (2003) 1925-1937
33. Ricote M., and Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 1771 (2007) 926-935
34. Vidal-Puig A., Jimenez-Linan M., Lowell B.B., Hamann A., Hu E., Spiegelman B., Flier J.S., and Moller D.E. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97 (1996) 2553-2561
35. Wei M., Arnold L., Cano M., and Cohen S.M. Effects of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium. Toxicol. Sci. 83 (2005) 237-245
36. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43 (2000) 527-550
37. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341-367
38. Xin X., Yang S., Kowalski J., and Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274 (1999) 9116-9121
39. Yang Q., Nagano T., Shah Y., Cheung C., Ito S., and Gonzalez F.J. The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol. Sci. 101 (2008) 132-139
40. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118